Lv32
280 积分 2023-04-18 加入
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
1天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
6天前
已完结
Drug-tolerant persister cells in cancer: the cutting edges and future directions
21天前
已完结
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
26天前
已完结
Blood–tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy
29天前
已完结
Systemic Therapy for Lung Cancer Brain Metastases
29天前
已完结
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
1个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
1个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
1个月前
已完结
Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape
1个月前
已完结
皖公网安备34019202002308
